Nektar Therapeutics (NKTR) Operating Leases (2019 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Operating Leases of $60.6 million for Q1 2026, down 22.76% year-over-year from $78.5 million in Q1 2025, and down 7.09% quarter-over-quarter from $65.3 million in Q4 2025.
Nektar Therapeutics (NKTR) Operating Leases (2019 - 2026) Analysis & Trends
Nektar Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $60.6 million for Q1 2026.
- In Q1 2026, Operating Leases fell 22.76% year-over-year to $60.6 million; the TTM figure through Mar 2026 stood at $60.6 million (down 22.76% YoY), while the FY2025 annual figure was $65.3 million, down 21.09% from the prior year.
- Operating Leases for Q1 2026 stood at $60.6 million, down from $65.3 million in the prior quarter.
- The five-year high for Operating Leases was $122.6 million in Q1 2022, with the low at $60.6 million in Q1 2026.
- The 5-year median for Operating Leases is $94.7 million (2024), against an average of $93.5 million.
- The sharpest annual moves came in 2022 and 2026: Operating Leases declined 8.86% in 2022, then declined 22.76% in 2026.
- Nektar Therapeutics' Operating Leases stood at $112.8 million in 2022, then declined by 12.68% to $98.5 million in 2023, then fell by 16.06% to $82.7 million in 2024, then dropped by 21.09% to $65.3 million in 2025, then dropped by 7.09% to $60.6 million in 2026.
- Business Quant data shows NKTR's Operating Leases at $60.6 million in Q1 2026, $65.3 million in Q4 2025, and $69.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.63 Mn |
| Dec 31, 2025 | 65.26 Mn |
| Sep 30, 2025 | 69.73 Mn |
| Jun 30, 2025 | 74.15 Mn |
| Mar 31, 2025 | 78.50 Mn |
| Dec 31, 2024 | 82.70 Mn |
| Sep 30, 2024 | 86.76 Mn |
| Jun 30, 2024 | 90.76 Mn |
| Mar 31, 2024 | 94.71 Mn |
| Dec 31, 2023 | 98.52 Mn |
| Sep 30, 2023 | 102.19 Mn |
| Jun 30, 2023 | 105.82 Mn |
| Mar 31, 2023 | 109.39 Mn |
| Dec 31, 2022 | 112.83 Mn |
| Sep 30, 2022 | 116.15 Mn |
| Jun 30, 2022 | 119.42 Mn |
| Mar 31, 2022 | 122.64 Mn |
| Dec 31, 2021 | 125.74 Mn |
| Sep 30, 2021 | 128.72 Mn |
| Jun 30, 2021 | 131.66 Mn |